Skip to content
Sunday 23 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,816.56
+0.64%
DAX
26,136.56
+0.59%
CAC 40
8,484.43
+0.37%
STOXX 50
6,462.22
+0.63%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 09 November 2011 7:40 pm

Prohibition fuels firestorm of new dangerous drugs

By: KCS-content

Add as a preferred source on Google

IN THE restless pursuit of pleasure, human beings will try almost any substance when circumstances require. During prohibition, Americans resorted to drinking toxic moonshine and inhaling ether. Second-rate substitutes and legal highs are seldom as pleasant as the real thing and are sometimes more dangerous, but at least you don’t have to worry about getting arrested.

The designer drugs that have swept Europe in the last two decades are the modern equivalent of moonshine, aided by the growth of the internet and the waning purity of ecstasy pills. Between 2003 and 2008, the MDMA content of ecstasy fell from 67 per cent to 33 per cent at a time when illicit chemists were synthesising dozens of new recreational substances. Ketamine, GHB, GBL, BZP and mephedrone all generated their own minor moral panics and were banned, only to be replaced by the likes of naphyrone, MDAI and Ivory Wave. More will follow. Twenty-four new legal highs were synthesised in 2009, with a further thirty-three appearing in 2010.

Although billed as “party drugs”, these chemicals often have little in common. Clubbers might use them interchangeably but mephedrone (Meow Meow) and BZP are stimulants, while GHB and ketamine are heavy sedatives. Different in nature and unpredictable in potency, users are vulnerable to overdose. Naphyrone (NRG-1) is active at just 20 milligrams while mephedrone is active at 200 milligrams. Since naphyrone was touted as “the new Meow Meow” when it appeared in 2010, users were liable to take ten times the “safe” dose. Some did.

Despite immense efforts by police, customs officers and legislators, there has been no decline in the nation’s consumption of illicit chemicals since the ecstasy panic peaked fifteen years ago. What we have instead is an ever-widening menu of narcotics about which users and authorities know little.

One proposed solution is to introduce a law similar to the USA’s Analog Act which automatically bans drugs which are “substantially similar” to banned substances. The idea is tempting in its simplicity, but this Nixon-era legislation is too vague to be legally useful and has rarely been invoked. The grey market continues to be one step ahead of legislation.

An alternative solution was proposed last week by Dr James Bell, of the South London and Maudsley NHS Foundation Trust, who suggested abandoning the unwinnable war against chemistry in favour of legalisation. All calls for drug liberalisation fall on stony political ground and Bell’s was no different, but there would be no better way of stopping the flood of dubious chemicals than a regulated free market. These drugs are nobody’s first choice. BZP was originally a worming tablet for cattle. Ketamine was a veterinary anaesthetic. GBL was a superglue remover. In all likelihood, that is what they would have remained had ecstasy not been banned.

Nobody made 80 per cent proof gin in their bathtubs after prohibition was repealed in 1933. Instead, Americans turned from distilled spirits to beer, the number of alcohol poisonings fell and the murder rate subsided. There is a lesson there for those fighting against narcotic moonshine today.

Chris Snowdon is an author and freelance journalist. His latest book is The Art of Suppression: Pleasure, Panic and Prohibition Since 1800.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Opinion

Categories

  • Opinion

Related Topics

  • NULL

Trending Articles

  • House prices in wealthy London boroughs fall by up to £300,000

  • Ratcliffe’s Ineos saves Runcorn plant

  • Amazon says it buys books in bulk to ‘improve products’

  • Mike Ashley’s Frasers offers to pay personal shoppers in Harvey Nichols takeover

  • As it happened: FTSE 100 rallies after JD Sports drags on blue chips; oil jumps again

More from Morning Wire

  • What Burnham’s Sporting Events Bill means for brands and media owners

    Sport Business
    Andy Burnham, Mayor of Greater Manchester, in glasses, showing enthusiasm at a sporting event.
  • The Simon Levy case proves some criminals can never be rehabilitated

    Opinion
    Simon Levy, a man with dark hair and a beard, looking directly at the camera.
  • Rolls-Royce Spectre Series II review: Driving a Rolls on a racetrack – yes, really…

    Life&Style
    Light blue Rolls-Royce Spectre electric coupe driving fast on a race track under a cloudy sky.
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • The Debate: should we release female prisoners to make space for men?

    Opinion
    Brick prison wall with barred windows, razor wire, and a security camera.
  • Mark Kleinman: English football’s New Deal heads into injury time

    Business
    Mark Kleinman is Sky News' City Editor and writes a column for Morning Wire
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • ‘Absurd’: Government seeks quantum tech chief – no experience necessary

    Tech
    Advanced quantum computer with intricate circuits and glowing interface, illustrating cutting-edge technology innovations
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook